Drug intelligence / Profile preview

AVT19

Development stage: Preclinical
Lead developer: Alvotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AVT19 is a monoclonal antibody biosimilar candidate to dupilumab (Dupixent), currently under development by Alvotech. It is designed to treat type 2 inflammatory diseases by targeting the interleukin-4 receptor alpha (IL-4Rα) subunit. By binding to IL-4Rα, AVT19 inhibits the signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of the inflammatory response in conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The drug is intended for subcutaneous administration. Alvotech has established a partnership with Advanz Pharma for the commercialization of AVT19 in Europe and other select markets.

Other names: dupilumab biosimilar

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on AVT19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVT19.

Explore the full profile